Novo Rebrands Diabetes Pill as Ozempic to Tap Blockbuster Name, Bloomberg Reports

TigerMay 1, 2026 12:16 PM

View all comments（0）



Novo Nordisk is rebranding an existing, less-popular diabetes tablet as Ozempic in the US in a bid to capitalize on the brand recognition of one of the world’s best-selling drugs, Bloomberg reported.

The Danish drugmaker will start selling Ozempic pills in doses of 1.5 milligram, 4 mg and 9 mg to adults from Monday through more than 70,000 pharmacies across the US, according to a statement Friday.

Novo Nordisk shares rose 2.8% in premarket trading.

Novo said the relaunched Ozempic pills are as safe and effective as tablets sold under the name Rybelsus, which have the same main ingredient, semaglutide, but in a different formulation and set of doses. Rybelsus will continue to be marketed outside the US.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

AMD vs. Broadcom: Which AI Chip Stock Is Better for Long-Term Investment? Comprehensive Comparison of AMD and AVGO

TradingKey - As AI data center investment continues to grow, both AMD (AMD) and Broadcom (AVGO) have emerged as key AI chip plays alongside Nvidia (NVDA), but the two companies have distinct business models. AMD primarily competes in the general-purpose AI computing market through its Instinct GPUs, EPYC server CPUs, and Helios rack systems, while Broadcom focuses on developing custom AI accelerators (ASIC/XPU) for major clients such as Google (GOOGL), OpenAI, and Anthropic, alongside high-speed networking chips. So, which of these two companies is the better long-term investment?

Apple Stock Price Forecast: Where Is the Next Target Price After Record High as iPhone 18 Pro Series Demand Heats Up?

Apple (AAPL) stock hit a record high on September 22, Eastern Time, just 10 days after Apple's fall launch event. However, how far this rally can go depends not on the product event, but on the actual demand for the iPhone 18 Pro series. JPMorgan's latest research report provided the first positive signal: the global average delivery wait time for the iPhone 18 Pro extended from 7 days in the first week to 23 days in the second week, with order momentum surpassing that of the iPhone 17 series over the same period last year.

Meta Stock Forecast: Muse Monetization Path Is Key as JPMorgan Raises Price Target to $920; Can Stock Hit Record High?

On September 24, Eastern Time, Meta Platforms (META) reached an intraday price of $777.89, hitting a nearly one-year high. Following the Meta Connect event, JPMorgan raised its price target on the company from $820 to $920 while maintaining an Overweight rating. The core reason is that the monetization path for Muse is becoming increasingly clear, leaving the bank more optimistic about Meta's growth potential beyond advertising.

Micron Earnings Preview: Five Key Things Memory Investors Need to Watch

TradingKey - Micron Technology (MU) will report its fourth-quarter fiscal 2026 financial results after the market close on September 30, Eastern Time, and hold an earnings conference call at 16:30 on the same day.

Meta Connect 2026 New Product Roundup: Muse Integrated Into AI Glasses, Can It Drive Meta Revenue Growth?

TradingKey - At the Connect 2026 conference held from September 23 to 24, Meta (META) unveiled the Ray-Ban Meta Audio, third-generation Ray-Ban Meta, and Meta VR Glasses, while upgrading the Meta Ray-Ban Display. The company also announced the integration of its personal AI agent, Muse, into its AI glasses, expanding its product scope from mobile phones and social apps to wearable devices.

Featured Tools